[go: up one dir, main page]

GB9914326D0 - Materials and methods relating to the diagnosis and treatment of pre-eclampsia - Google Patents

Materials and methods relating to the diagnosis and treatment of pre-eclampsia

Info

Publication number
GB9914326D0
GB9914326D0 GBGB9914326.5A GB9914326A GB9914326D0 GB 9914326 D0 GB9914326 D0 GB 9914326D0 GB 9914326 A GB9914326 A GB 9914326A GB 9914326 D0 GB9914326 D0 GB 9914326D0
Authority
GB
United Kingdom
Prior art keywords
eclampsia
treatment
diagnosis
materials
adpase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9914326.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rademacher Group Ltd
Original Assignee
Rademacher Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rademacher Group Ltd filed Critical Rademacher Group Ltd
Priority to GBGB9914326.5A priority Critical patent/GB9914326D0/en
Publication of GB9914326D0 publication Critical patent/GB9914326D0/en
Priority to PCT/GB2000/002333 priority patent/WO2000078330A2/en
Priority to JP2001504393A priority patent/JP2003502381A/en
Priority to EP00940550A priority patent/EP1185295A2/en
Priority to CA002368099A priority patent/CA2368099A1/en
Priority to AU55472/00A priority patent/AU5547200A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD, ATP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Analytical Chemistry (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)

Abstract

The present invention relates to materials and methods for the diagnosis and treatment of pre-eclampsia and related conditions characterised by platelet aggregation. In particular it relates to the use of adenosine diphosphatase (ADPase) and activators of ADPase for the treatment of pre-eclampsia, in order to overcome the inhibition of ADPase by inositol phosphoglycans (IPGs). Also provided is a method for screening for compounds with ADPase-stimulatory activity in the presence or absence of IPGs.
GBGB9914326.5A 1999-06-18 1999-06-18 Materials and methods relating to the diagnosis and treatment of pre-eclampsia Ceased GB9914326D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB9914326.5A GB9914326D0 (en) 1999-06-18 1999-06-18 Materials and methods relating to the diagnosis and treatment of pre-eclampsia
PCT/GB2000/002333 WO2000078330A2 (en) 1999-06-18 2000-06-16 Adenosine diphosphatase and activators thereof and their medical uses
JP2001504393A JP2003502381A (en) 1999-06-18 2000-06-16 Adenosine diphosphatase and activators thereof, and their medical uses
EP00940550A EP1185295A2 (en) 1999-06-18 2000-06-16 Adenosine diphosphatase and activators thereof and their medical uses
CA002368099A CA2368099A1 (en) 1999-06-18 2000-06-16 Adenosine diphosphatase and activators thereof and their medical uses
AU55472/00A AU5547200A (en) 1999-06-18 2000-06-16 Adenosine diphosphatase and activators thereof and their medical uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9914326.5A GB9914326D0 (en) 1999-06-18 1999-06-18 Materials and methods relating to the diagnosis and treatment of pre-eclampsia

Publications (1)

Publication Number Publication Date
GB9914326D0 true GB9914326D0 (en) 1999-08-18

Family

ID=10855663

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9914326.5A Ceased GB9914326D0 (en) 1999-06-18 1999-06-18 Materials and methods relating to the diagnosis and treatment of pre-eclampsia

Country Status (6)

Country Link
EP (1) EP1185295A2 (en)
JP (1) JP2003502381A (en)
AU (1) AU5547200A (en)
CA (1) CA2368099A1 (en)
GB (1) GB9914326D0 (en)
WO (1) WO2000078330A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053715A2 (en) * 2001-01-02 2002-07-11 Bayer Aktiengesellschaft Nucleoside diphosphate hydrolase
ES2718905T3 (en) * 2012-04-24 2019-07-05 Siemens Healthcare Diagnostics Inc Preeclampsia test methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815252A1 (en) * 1995-03-24 1998-01-07 Novartis AG Gene therapy for transplantation and inflammatory or thrombotic conditions
GB9618931D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in pre-eclampsia and diabetes
WO2000023094A2 (en) * 1998-10-16 2000-04-27 Immunex Corporation Methods of inhibiting platelet activation and recruitment

Also Published As

Publication number Publication date
EP1185295A2 (en) 2002-03-13
WO2000078330A2 (en) 2000-12-28
WO2000078330A3 (en) 2001-05-25
JP2003502381A (en) 2003-01-21
CA2368099A1 (en) 2000-12-28
AU5547200A (en) 2001-01-09

Similar Documents

Publication Publication Date Title
AU9058091A (en) Preparation of nucleic acid samples
HU9601593D0 (en) Solution phase nucleic acid sandwich assays having reduced background noise
SG138449A1 (en) Enumeration method for the link clock rate and the pixel/audio clock rate
TW200741000A (en) Method of producing lymphocytes
AU568233B2 (en) Non-condensible gas process for the enhanced recovery of hydrocarbons
WO2007127936A3 (en) Methods and compositions for antibody therapy
IE890181L (en) Removal of steroids
AU4310297A (en) Materials and methods relating to the diagnosis and treatment of pre-eclampsia and diabetes
TW200517501A (en) Process for producing cytotoxic lymphocytes
CA2026902A1 (en) Process for nitrocarburizing components made from steel
ES8300136A1 (en) Process and reagent for determining cholesterol.
BR8702649A (en) BIOCIDAL COMPOSITION, PROCESS FOR INHIBITING THE GROWTH OF MICROORGANISMS, MEDIUM, LEATHER OR WOOD, COMPOUND AND FERRO COMPLEX
GB9914326D0 (en) Materials and methods relating to the diagnosis and treatment of pre-eclampsia
WO2003076037A3 (en) Selective elution of immobilized multiplexed primer extension products
EP0127393A3 (en) Flexible microdrill
ATE250630T1 (en) CRYSTALS OF FRAGMENTS OF CD40 LIGANDS AND THEIR USE
WO2022082178A3 (en) Methods for treating and monitoring frontotemporal dementia
ATE109623T1 (en) METHODS TO COMBAT MICROORGANISMS.
HU9301316D0 (en) Method for application of prothrombin fragments
MY132876A (en) Method for visually demonstrating the effectiveness of an anti-bacteria attachment composition
ATE176280T1 (en) ENZYMATIC PROCESS FOR PRODUCING MORPHIN-6-GLUCURONIDES OR SUBSTITUTED MORPHIN-6-GLUCURONIDES
PT83368A (en) Process for propagating microorganisms in vivo by using cell lines which lack human class ii histocompatibility antigens
NZ312625A (en) Method for the production of thrombin from a prothrombin containing material
UA41910C2 (en) METHOD FOR Isolation of CEFACLOR OR ITS SALT FROM THE MIXTURE AFTER THE ENZYME ACYLATION REACTION
EP0114160A3 (en) Process for the enzymatic saccharification of raw materials, containing starch

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)